Navigation Links
Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohn's Disease in the European Union
Date:3/7/2013

efore, vedolizumab, by preventing this interaction, has a gut selective effect.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, http://www.takeda.com.

This press release contains forward-looking statements. Forward-looking statements include statements regarding Takeda's plans, outlook, strategies, results for the future, and other statements that are not descriptions of historical facts. Forward-looking statements may be identified by the use of forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "assume," "continue," "seek," "pro forma," "potential," "target," "forecast," "guidance," "outlook" or "intend" or other similar words or expressions of the negative thereof. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors are cautioned not to unduly rely on such forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to, (1) the economic circumstances surrounding Takeda's business, including general economic conditions in Japan, the United States and worldwide; (2) competitive pressur
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
2. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
3. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
4. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
5. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
6. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
7. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
8. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
9. Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
10. Bayer Submits New Drug Application for Riociguat for the Treatment of Pulmonary Arterial Hypertension and Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
11. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was ... in which he has overseen the company,s four facilities ... , and Costa Rica.  Mr. King joined Tegra ... sales, engineering and manufacturing experience in medical device businesses, ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ... fueled rapid growth of these markets. ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ... very important aspects in today,s growth in ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... 5 Cardiac Science Corporation (Nasdaq: ... ( AED ) and diagnostic cardiac monitoring devices, ... Jr., to its board of directors. Andrews replaces long-time board ... seat effective November 5th. The total number of directors remains ...
... SAN DIEGO, Nov. 5 ResMed Inc. (NYSE: RMD ... quarter ended September 30, 2009. Revenue for the September 2009 ... on a constant currency basis) over the quarter ended September ... from operations was $52.7 million and net income was $42.1 ...
Cached Medicine Technology:Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors 2Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors 3Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors 4Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors 5ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2009 2ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2009 3ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2009 4ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2009 5ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2009 6ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2009 7
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... Just a Nicety; Vacations are a Necessity, ... the,long-term benefits associated with taking regular vacations contribute ... the statistics,are astounding. Men who don,t vacation regularly ... attacks; women are 50 percent more likely.(1) In ...
... World Psoriasis,Day, Oct. 29, the National Psoriasis Foundation ... http://www.psoriasis.org, and sign up to support,increased research ... system that appears on the skin., During ... will,occur all over the world to help increase ...
... Oct. 28 HMS Holdings Corp. (Nasdaq:,HMSY) today announced ... Conference, which will be held November 3-4, 2008 at ... CEO and Walter Hosp, CFO, will present on Tuesday,November ... Corp. (Nasdaq: HMSY ) is the nation,s leader ...
... Corporation ( www.aegiscorp.com ), a leading provider of Manufacturing Process ... executive vice president and chief science officer, and Joe Rothman, ... at two global life sciences industry events in Germany and ... ...
... . , Montreal, October 28, 2008 - Patients 80 ... perfectly able to withstand open-heart surgery, according to the latest ... Centre (MUHC). His findings were presented this morning in Toronto ... be a reason for doctors to rule out the possibility ...
... 28 A new research study just published in,a ... Type 2,diabetes almost doubled over the last six years. ... prevention services, say the,actual costs are far higher and ... costs low and more people healthy., (Logo: ...
Cached Medicine News:Health News:Video: Regular Vacations: Prescription for a Healthy Lifestyle 2Health News:Video: Regular Vacations: Prescription for a Healthy Lifestyle 3Health News:National Psoriasis Foundation Seeks 10,000 Americans to Support Psoriasis Research for World Psoriasis Day 2Health News:National Psoriasis Foundation Seeks 10,000 Americans to Support Psoriasis Research for World Psoriasis Day 3Health News: Aegis to Present on Global Stages : Company to Discuss How Manufacturing Process IntelligenceSupports Tech Transfer and Product Lifecycle Management 2Health News: Aegis to Present on Global Stages : Company to Discuss How Manufacturing Process IntelligenceSupports Tech Transfer and Product Lifecycle Management 3Health News:U.S. Preventive Medicine Says Prevention Can Keep Diabetes Costs From Rising 2
Cemented foundation 460 series....
Porous foundation 440 series....
The AcuMatch M-Series modular femoral stem is a unique, innovative three-piece modular stem designed to address even the most complicated of clinical indications....
A cementless femoral stem that promotes bone in-growth and reduces thigh pain....
Medicine Products: